SAN RAMON, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan M. N. Rigby, President and Chief Executive Officer, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 16, 2017 at 9:10 a.m. EDT. Management will also be available for one-on-one meetings at the conference.
A webcast of the Company’s presentation will be available on the investor relations section of SteadyMed’s website at www.steadymed.com. A webcast replay of the presentation will be available for 90 days.
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's pre-filled, sterile, single use, disposable, PatchPump® infusion system, with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Senior Director, Investor Relations and Marketing
The Ruth Group